Realtime-Estimate
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
12’353 GBX | +0.28% | +2.05% | +16.66% |
14:05 | JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence | DP |
13.05. | AstraZeneca von Studienteilnehmer wegen angeblicher Verletzung während der COVID-19-Impfstoffstudie verklagt | MT |
Kurzporträt
- Produktverkäufe (95,6%). Die Nettoumsätze verteilen sich auf die Behandlungsbereiche Onkologie (39,2%), Herz-Kreislauf-, Nieren- und Stoffwechselerkrankungen (24,2%), Atemwegs- und Autoimmunerkrankungen (13,9%) und Sonstige (22,7%; Entzündungskrankheiten, neurologische Erkrankungen, Magen-Darm- und Infektionskrankheiten);
- Einnahmen aus Kooperationen (4,4%).
Der Nettoumsatz verteilt sich geografisch wie folgt: Großbritannien (7,4%), Europa (21,2%), Amerika (45,3%) und Afrika-Asien-Australien (26,1%).
Mitarbeiterzahl: 89 900
Umsatz nach Geschäftsbereich
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Oncology
37,4
%
| 11 878 | 33,0 % | 13 793 | 37,4 % | +16.12% |
Cardiovascular, Renal and Metabolism
23,1
%
| 7 459 | 20,7 % | 8 515 | 23,1 % | +14.16% |
Rare Disease
16,9
%
| 5 726 | 15,9 % | 6 246 | 16,9 % | +9.08% |
Respiratory and Immunology
13,3
%
| 4 680 | 13,0 % | 4 913 | 13,3 % | +4.97% |
Alliance
3,1
%
| - | - | 1 149 | 3,1 % | - |
Other Medicines
2,6
%
| 1 319 | 3,7 % | 946 | 2,6 % | -28.29% |
Vaccines and Immune Therapies
2,2
%
| 3 845 | 10,7 % | 814 | 2,2 % | -78.83% |
Collaboration
1,3
%
| 1 098 | 3,1 % | 478 | 1,3 % | -56.50% |
Umsatz je Region
GBP in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
39,6
%
| 14 027 | 39,0 % | 14 578 | 39,6 % | +3.93% |
China
12,8
%
| 4 662 | 12,9 % | 4 724 | 12,8 % | +1.32% |
Japan
7,9
%
| 3 236 | 9,0 % | 2 928 | 7,9 % | -9.51% |
United Kingdom
7,4
%
| 2 530 | 7,0 % | 2 709 | 7,4 % | +7.07% |
Other Rest of Europe
6,8
%
| 2 197 | 6,1 % | 2 502 | 6,8 % | +13.89% |
Germany
4,6
%
| 1 544 | 4,3 % | 1 689 | 4,6 % | +9.36% |
Other Asia, Africa and Australasia
4,5
%
| 1 953 | 5,4 % | 1 645 | 4,5 % | -15.77% |
Sweden
3,7
%
| 1 397 | 3,9 % | 1 371 | 3,7 % | -1.89% |
Other Americas
3,7
%
| 954 | 2,6 % | 1 354 | 3,7 % | +41.94% |
France
2,5
%
| 899 | 2,5 % | 927 | 2,5 % | +3.12% |
Canada
2,1
%
| 947 | 2,6 % | 778 | 2,1 % | -17.82% |
Spain
1,8
%
| 599 | 1,7 % | 681 | 1,8 % | +13.73% |
Italy
1,8
%
| 597 | 1,7 % | 654 | 1,8 % | +9.61% |
Australia
0,9
%
| 464 | 1,3 % | 314 | 0,9 % | -32.32% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01.10.12 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01.08.21 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01.01.20 |
Sharon Barr
CTO | Chief Tech/Sci/R&D Officer | - | 01.08.23 |
Regina Danielson
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Chief Tech/Sci/R&D Officer | - | 18.05.23 | |
Pam Cheng
COO | Chief Operating Officer | 53 | 01.06.15 |
Jeffrey Pott
CMP | Compliance Officer | - | 01.01.95 |
Corporate Officer/Principal | 63 | 01.01.02 | |
Iskra Reic
PRN | Corporate Officer/Principal | - | 01.01.01 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01.10.17 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01.02.13 |
Philip Broadley
BRD | Director/Board Member | 63 | 27.04.17 |
Director/Board Member | 68 | 01.04.99 | |
Marc Dunoyer
PRN | Corporate Officer/Principal | 71 | 01.06.13 |
Andreas Rummelt
BRD | Director/Board Member | 66 | 01.08.21 |
Michel Demaré
CHM | Chairman | 67 | 01.09.19 |
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01.10.12 |
Deborah DiSanzo
BRD | Director/Board Member | 64 | 01.12.17 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01.08.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 1 550 235 025 | 1 495 910 888 ( 96,50 %) | 0 | 96,50 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
18 750 000 | 75,00% | 1 200 298 875 $ | |
32 100 518 | 9,06% | 834 691 151 $ | |
108 923 023 | 37,58% | 677 619 929 $ | |
NIOX GROUP PLC 16,81% | 71 065 878 | 16,81% | 63 179 698 $ |
CELLECTIS S.A. 22,30% | 16 000 000 | 22,30% | 41 657 920 $ |
ADC THERAPEUTICS SA 4,84% | 4 011 215 | 4,84% | 17 809 795 $ |
INNATE PHARMA 9,26% | 7 485 500 | 9,26% | 17 648 563 $ |
44 803 | 3,62% | 519 715 $ | |
884 956 | 1,99% | 57 522 $ |
Unternehmenskontakt
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA, Cambridge
+44 20 3749 5000
http://www.astrazeneca.co.ukKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. |
Miscellaneous Commercial Services
|
Pharmaceuticals: Major
| |
AstraZeneca UK Ltd.
AstraZeneca UK Ltd. Miscellaneous Commercial ServicesCommercial Services AstraZeneca UK Ltd. manufactures pharmaceutical products. Its products are used to treat cardiovascular diseases, diabetes, and gastrointestinal infections. The company was founded on November 26, 1998 and is headquartered in London, the United Kingdom. |
Miscellaneous Commercial Services
|
R&Q Beta Co. Plc
R&Q Beta Co. Plc Insurance Brokers/ServicesFinance R&Q Beta Co. Plc provides insurance services. The company was founded in 1994 and is headquartered in Cambridge, the United Kingdom. |
Insurance Brokers/Services
|
AstraZeneca India Pvt Ltd.
AstraZeneca India Pvt Ltd. Pharmaceuticals: MajorHealth Technology AstraZeneca India Pvt Ltd. operates as a biopharmaceutical company. The company was founded in 1979 and is headquartered in Bangalore, India. |
Pharmaceuticals: Major
|
Astrazeneca Holdings BV
| |
AstraZeneca Share Trust Ltd.
AstraZeneca Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Share Trust Ltd. is a British company that provides business support services. The private company is located in the UK. |
Miscellaneous Commercial Services
|
AstraZeneca Employee Share Trust Ltd.
AstraZeneca Employee Share Trust Ltd. Miscellaneous Commercial ServicesCommercial Services Part of AstraZeneca PLC, AstraZeneca Employee Share Trust Ltd. is a British company that provides business support services. The private company is located in the UK. |
Miscellaneous Commercial Services
|
Astrazeneca Treasury BV
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+16.66% | 240 Mrd. | |
+29.89% | 682 Mrd. | |
+30.71% | 586 Mrd. | |
-3.30% | 364 Mrd. | |
+17.94% | 327 Mrd. | |
+4.19% | 285 Mrd. | |
+9.96% | 209 Mrd. | |
-8.67% | 203 Mrd. | |
+7.09% | 165 Mrd. | |
-0.99% | 161 Mrd. |
- Börse
- Aktien
- 886455 Aktie
- Unternehmen AstraZeneca PLC